[go: up one dir, main page]

NO20091966L - Sammensetninger og fremgangsmater for a redusere proliferasjon av endometrie - Google Patents

Sammensetninger og fremgangsmater for a redusere proliferasjon av endometrie

Info

Publication number
NO20091966L
NO20091966L NO20091966A NO20091966A NO20091966L NO 20091966 L NO20091966 L NO 20091966L NO 20091966 A NO20091966 A NO 20091966A NO 20091966 A NO20091966 A NO 20091966A NO 20091966 L NO20091966 L NO 20091966L
Authority
NO
Norway
Prior art keywords
methods
present
compositions
estrogen
endometrial
Prior art date
Application number
NO20091966A
Other languages
English (en)
Other versions
NO342085B1 (no
Inventor
Joseph Podolski
Original Assignee
Repros Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Repros Therapeutics Inc filed Critical Repros Therapeutics Inc
Publication of NO20091966L publication Critical patent/NO20091966L/no
Publication of NO342085B1 publication Critical patent/NO342085B1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/34—Gestagens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/36—Antigestagens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Endocrinology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Reproductive Health (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Gynecology & Obstetrics (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)

Abstract

Foreliggende oppfinnelse vedrører feltet hormonterapi. Nærmere bestemt vedrører foreliggende oppfinnelse fremgangsmåter for behandling av slike østrogenavhengige tilstander som endometrie-hyperplasi og endometrie-cancer i en kvinne som gjennomgår østrogen- og/eller selektiv østrogenreseptormodulator- (SERM) terapi. Foreliggende oppfinnelse er også relevant for undertrykkelsen av endometrie-proliferasjon. Foreliggende oppfinnelse er også relevant for behandlingen av smerte assosiert med endometriose. Sammensetningene for gjennomføring av fremgangsmåtene omfattende progesteronantagonist, er også angitt. Utførelsesformer av foreliggende oppfinnelse angir også fremgangsmåter for identifisering av nye selektive progesteronreseptormodulatorer for gjennomføring av angitte behandlingsmåter.
NO20091966A 2006-10-24 2009-05-20 Progesteronantagonist for anvendelse ved medisinsk behandling for undertrykking av endometrieproliferasjon eller forebygging av hyperproliferasjon av uterinceller NO342085B1 (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US86263206P 2006-10-24 2006-10-24
US88534807P 2007-01-17 2007-01-17
PCT/US2007/082432 WO2008067086A2 (en) 2006-10-24 2007-10-24 Compositions and methods for suppressing endometrial proliferation

Publications (2)

Publication Number Publication Date
NO20091966L true NO20091966L (no) 2009-07-21
NO342085B1 NO342085B1 (no) 2018-03-19

Family

ID=39468586

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20091966A NO342085B1 (no) 2006-10-24 2009-05-20 Progesteronantagonist for anvendelse ved medisinsk behandling for undertrykking av endometrieproliferasjon eller forebygging av hyperproliferasjon av uterinceller

Country Status (25)

Country Link
US (3) US9283234B2 (no)
EP (3) EP3263112B1 (no)
JP (5) JP2010507685A (no)
KR (1) KR20090067198A (no)
AU (1) AU2007327707B2 (no)
BR (1) BRPI0717747A2 (no)
CA (1) CA2673128C (no)
CR (1) CR10826A (no)
CY (2) CY1119521T1 (no)
DK (2) DK2078032T3 (no)
EA (1) EA017227B1 (no)
EC (1) ECSP099349A (no)
ES (2) ES2643318T3 (no)
HK (1) HK1216849A1 (no)
HU (2) HUE051484T2 (no)
IL (2) IL197893A (no)
LT (2) LT2078032T (no)
MX (2) MX343130B (no)
MY (1) MY150763A (no)
NO (1) NO342085B1 (no)
NZ (1) NZ576274A (no)
PL (2) PL2078032T3 (no)
PT (2) PT3263112T (no)
SI (2) SI3263112T1 (no)
WO (1) WO2008067086A2 (no)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5193196B2 (ja) 2006-06-02 2013-05-08 ペア ツリー ウーマンズ ヘルス ケア 萎縮性膣炎の治療の方法
ES2643318T3 (es) * 2006-10-24 2017-11-22 Repros Therapeutics Inc. Composiciones y métodos para suprimir la proliferación endometrial
TW201002736A (en) * 2008-04-28 2010-01-16 Repros Therapeutics Inc Compositions and methods for treating progesterone-dependent conditions
TWI477276B (zh) * 2008-04-28 2015-03-21 Repros Therapeutics Inc 抗黃體素給藥方案
RU2373977C1 (ru) * 2008-08-05 2009-11-27 Государственное образовательное учреждение дополнительного профессионального образования "Новокузнецкий государственный институт усовершенствования врачей Федерального агентства по здравоохранению и социальному развитию" Способ лечения болевого синдрома при викарном увеличении яичника после односторонней аднексэктомии
US8512745B2 (en) 2008-12-08 2013-08-20 Laboratoire Hra Pharma Ulipristal acetate tablets
UA113283C2 (xx) * 2010-12-23 2017-01-10 19-норстероїди і їх застосування для лікування прогестеронзалежних станів
EP2471537A1 (en) * 2010-12-30 2012-07-04 PregLem S.A. Treatment of pain associated with dislocation of basal endometrium
MX363640B (es) 2012-05-31 2019-03-28 Repros Therapeutics Inc Formulaciones y metodos para la administracion vaginal de antiprogestinas.
WO2014070517A1 (en) 2012-11-02 2014-05-08 Repros Therapeutics Inc. Methods and compositions for treating progesterone-dependent conditions
FR2997628B1 (fr) * 2012-11-08 2015-01-16 Hra Pharma Lab Produit de co-micronisation comprenant un modulateur selectif des recepteurs a la progesterone
HK1221169A1 (zh) 2013-04-10 2017-05-26 Preglem S.A. 孕酮受体调节剂在子宫肌瘤疗法中的用途
US20190008804A1 (en) * 2016-01-12 2019-01-10 Repros Therapeutics Inc. Trans-Clomiphene and Progesterone Receptor Antagonist Combination Therapy for Treating Hormone-Dependent Conditions

Family Cites Families (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4038389A (en) * 1975-05-07 1977-07-26 The Upjohn Company Medroxyprogesterone acetate compositions
US4409208A (en) 1980-04-15 1983-10-11 The Salk Institute For Biological Studies GnRH antagonists
ZA8231B (en) 1981-01-09 1982-11-24 Roussel Uclaf New 11 -substituted steroid derivatives, their preparation, their use as medicaments, the compositions containing them and the new intermediates thus obtained
US4619914A (en) 1983-03-10 1986-10-28 The Salk Institute For Biological Studies GNRH antagonists IIIB
US4780461A (en) 1983-06-15 1988-10-25 Schering Aktiengesellschaft 13α-alkyl-gonanes, their production, and pharmaceutical preparations containing same
US4547370A (en) 1983-11-29 1985-10-15 The Salk Institute For Biological Studies GnRH Antagonists
DE3347126A1 (de) 1983-12-22 1985-07-11 Schering AG, 1000 Berlin und 4709 Bergkamen 11ss-aryl-estradiene, deren herstellung und diese enthaltende pharmazeutische praeparate
US4569927A (en) 1984-02-23 1986-02-11 The Salk Institute For Biological Studies GnRH Antagonists IV
US4565804A (en) 1984-09-07 1986-01-21 The Salk Institute For Biological Studies GnRH Antagonists VI
DE3506785A1 (de) 1985-02-22 1986-08-28 Schering AG, Berlin und Bergkamen, 1000 Berlin 11ss-n,n-dimethylaminophenyl-estradiene, deren herstellung und diese enthaltende pharmazeutische praeparate
DE3625315A1 (de) 1986-07-25 1988-01-28 Schering Ag 11ss-(4-isopropenylphenyl)-estra-4,9-diene, deren herstellung und diese enthaltende pharmazeutische praeparate
US5446178A (en) 1987-03-18 1995-08-29 Schering Aktiengesellschaft Process for preparing 19,11β-bridged steroids
DE3708942A1 (de) 1987-03-18 1988-09-29 Schering Ag 19,11ss-ueberbrueckte steroide, deren herstellung und diese enthaltende pharmazeutische praeparate
ES2045082T3 (es) 1987-04-24 1994-01-16 Akzo Nv Un metodo para la preparacion de nuevos derivados 11-arilestrano y 11-arilpregnano.
EP0321010B1 (en) 1987-12-12 1993-02-03 Akzo N.V. New 11-arylsteroid compounds
DE3820948A1 (de) 1988-06-16 1989-12-21 Schering Ag 10ss, 11ss-ueberbrueckte steroide
DE3822770A1 (de) 1988-07-01 1990-01-04 Schering Ag 13-alkyl-11ss-phenylgonane
DE3832303A1 (de) 1988-09-20 1990-04-12 Schering Ag 11ss-phenyl-14ssh-steroide
DE3917274A1 (de) 1989-05-24 1990-11-29 Schering Ag 9(alpha)-hydroxy-19, 11(beta)-ueberbrueckte steroide, deren herstellung und diese enthaltende pharmazeutische praeparate
DE3921059A1 (de) 1989-06-23 1991-01-10 Schering Ag 11(beta)-aryl-4-estrene, verfahren zu ihrer herstellung sowie deren verwendung als arzneimittel
DE4042007A1 (de) 1990-12-22 1992-06-25 Schering Ag 6,7-modifizierte-11(beta)-aryl-4-estrene
US5407928A (en) 1990-08-15 1995-04-18 Schering Aktiengesellschaft 11β-aryl-gona-4,9-dien-3-ones
DE4038128A1 (de) 1990-11-27 1992-06-04 Schering Ag 8-en-19, 11(beta)-ueberbrueckte steroide, deren herstellung und diese enthaltende pharmazeutische praeparate
ZA929315B (en) 1991-12-20 1993-05-24 Akzo Nv 17-spirofuran-3'-ylidene steroids.
DE4216003A1 (de) 1992-05-12 1993-11-18 Schering Ag Dissoziierte kompetitive Progesteronantagonisten
DE4216004B4 (de) 1992-05-12 2008-03-27 Bayer Schering Pharma Akiengesellschaft Verwendung kompetitiver Progesteronantagonisten
US5439913A (en) 1992-05-12 1995-08-08 Schering Aktiengesellschaft Contraception method using competitive progesterone antagonists and novel compounds useful therein
PT650480E (pt) 1992-07-01 2002-03-28 Ortho Pharma Corp 1-arilsulfonil-3-fenil-1,4,5,6-tetrahidropiridazinas
US5468736A (en) * 1993-02-25 1995-11-21 The Medical College Of Hampton Road Hormone replacement therapy
DE4332283A1 (de) 1993-09-20 1995-04-13 Jenapharm Gmbh Neue 11-Benzaldoximestradien-Derivate, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel
DE4332284C2 (de) 1993-09-20 1997-05-28 Jenapharm Gmbh 11-Benzaldoxim-17beta-methoxy-17alpha-methoxymethyl-estradien-Derivate, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel
US5681817A (en) * 1994-02-04 1997-10-28 The Medical College Of Hampton Roads Treatment of ovarian estrogen dependent conditions
DE4434488A1 (de) 1994-09-14 1996-03-21 Schering Ag Steroidester und -amide, Verfahren zu ihrer Herstellung und ihre pharmazeutische Verwendung
US5576310A (en) 1994-09-20 1996-11-19 Jenapharm Gmbh 11-benzaldoxime-17β-methoxy-17α-methoxymethyl-estrasdiene derivatives, methods for their production and pharmaceuticals containing such compounds
US5521166A (en) * 1994-12-19 1996-05-28 Ortho Pharmaceitical Corporation Antiprogestin cyclophasic hormonal regimen
US5693646A (en) 1994-12-22 1997-12-02 Ligand Pharmaceuticals Incorporated Steroid receptor modulator compounds and methods
US5780050A (en) * 1995-07-20 1998-07-14 Theratech, Inc. Drug delivery compositions for improved stability of steroids
AU710139B2 (en) 1996-05-01 1999-09-16 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The 21-substituted progesterone derivatives as new antiprogestational agents
US6900193B1 (en) 1996-05-01 2005-05-31 The United States Of America As Represented By The Department Of Health And Human Services Structural modification of 19-norprogesterone I: 17-α-substituted-11-β-substituted-4-aryl and 21-substituted 19-norpregnadienedione as new antiprogestational agents
US5753655A (en) 1996-10-10 1998-05-19 Ortho Pharmaceutical Corporation 1-arylsulphonyl, arylcarbonyl and arylthiocarbonyl pyridazino derivatives and methods of preparation
DE19652408C2 (de) 1996-12-06 2002-04-18 Schering Ag Steroidester, Verfahren zu ihrer Herstellung und ihre Verwendung zur Herstellung von Arzneimitteln
DE19706061A1 (de) 1997-02-07 1998-08-13 Schering Ag Antigestagen wirksame Steroide mit fluorierter 17alpha-Alkylkette
DE19809845A1 (de) 1998-03-03 1999-09-09 Jenapharm Gmbh S-substituierte 11beta-Benzaldoxim-estra-4,9-dien-kohlensäurethiolester, Verfahren zu deren Herstellung und diese Verbindungen enthaltende pharmazeutische Zubereitungen
US6020328A (en) * 1998-03-06 2000-02-01 Research Triangle Institute 20-keto-11β-arylsteroids and their derivatives having agonist or antagonist hormonal properties
US6689768B2 (en) * 1998-04-15 2004-02-10 Jenapharm Gmbh & Co. Kg Pharmaceutical preparations for treating side effects during and/or after GnRHa therapy
US6380235B1 (en) 1999-05-04 2002-04-30 American Home Products Corporation Benzimidazolones and analogues
US6369056B1 (en) 1999-05-04 2002-04-09 American Home Products Corporation Cyclic urea and cyclic amide derivatives
US6391907B1 (en) 1999-05-04 2002-05-21 American Home Products Corporation Indoline derivatives
US6306851B1 (en) 1999-05-04 2001-10-23 American Home Products Corporation Cyclocarbamate and cyclic amide derivatives
US6417214B1 (en) 1999-05-04 2002-07-09 Wyeth 3,3-substituted indoline derivatives
US6509334B1 (en) 1999-05-04 2003-01-21 American Home Products Corporation Cyclocarbamate derivatives as progesterone receptor modulators
US6339098B1 (en) 1999-05-04 2002-01-15 American Home Products Corporation 2,1-benzisothiazoline 2,2-dioxides
US6358948B1 (en) 1999-05-04 2002-03-19 American Home Products Corporation Quinazolinone and benzoxazine derivatives as progesterone receptor modulators
SE514556C2 (sv) 1999-07-09 2001-03-12 Jema Jori Ab Metod för hantering av en databas
US6768014B2 (en) 1999-12-29 2004-07-27 The United States Of America As Represented By The Department Of Health And Human Services PROCESS FOR PREPARING 17α-ACETOXY-11β-[4-N,N(DIMETHYLAMINO)PHENYL]-21-METHOXY-19-NORPREGNA-4,9-DIENE-3,20-DIONE, INTERMEDIATES USEFUL IN THE PROCESS , AND PROCESSES FOR PREPARING SUCH INTERMEDIATES
US7109171B2 (en) * 2000-02-28 2006-09-19 Praecis Pharmaceuticals Inc. Methods for treating FSH related conditions with GnRH antagonists
CA2403756C (en) * 2000-03-17 2010-02-09 Hyun K. Kim Structural modification of 19-norprogesterone i: 17-.alpha.-substituted, 11-.beta.-substituted-4-aryl and 21-substituted 19-norpregnadienedione as new antiprogestational agents
AU2005265357B2 (en) * 2004-07-09 2011-04-07 Laboratoire Hra Pharma Sustained release compositions containing progesterone receptor modulators
ES2643318T3 (es) * 2006-10-24 2017-11-22 Repros Therapeutics Inc. Composiciones y métodos para suprimir la proliferación endometrial

Also Published As

Publication number Publication date
MX2009003953A (es) 2009-04-28
US9616074B2 (en) 2017-04-11
ES2643318T3 (es) 2017-11-22
IL238823B (en) 2018-06-28
EP2078032A2 (en) 2009-07-15
DK2078032T3 (da) 2017-11-13
ECSP099349A (es) 2009-06-30
US9283234B2 (en) 2016-03-15
EP3693376A1 (en) 2020-08-12
PL2078032T3 (pl) 2018-01-31
DK3263112T3 (da) 2020-08-17
EP2078032B1 (en) 2017-08-02
EA200970409A1 (ru) 2009-10-30
HK1216849A1 (zh) 2016-12-09
CR10826A (es) 2009-09-29
US20140235602A1 (en) 2014-08-21
NO342085B1 (no) 2018-03-19
CA2673128C (en) 2018-07-03
JP2017203049A (ja) 2017-11-16
AU2007327707B2 (en) 2012-07-12
AU2007327707A1 (en) 2008-06-05
EP2078032A4 (en) 2011-09-14
CY1119521T1 (el) 2018-03-07
EP3263112B1 (en) 2020-05-13
CA2673128A1 (en) 2008-06-05
WO2008067086A2 (en) 2008-06-05
NZ576274A (en) 2011-12-22
JP2019131587A (ja) 2019-08-08
US20100216756A1 (en) 2010-08-26
LT2078032T (lt) 2017-11-10
PL3263112T3 (pl) 2021-01-11
PT2078032T (pt) 2017-11-10
WO2008067086A3 (en) 2008-11-06
EA017227B1 (ru) 2012-10-30
MY150763A (en) 2014-02-28
JP2010507685A (ja) 2010-03-11
LT3263112T (lt) 2020-10-12
BRPI0717747A2 (pt) 2013-10-22
KR20090067198A (ko) 2009-06-24
SI2078032T1 (sl) 2017-12-29
EP3263112A1 (en) 2018-01-03
SI3263112T1 (sl) 2020-10-30
JP2016183199A (ja) 2016-10-20
PT3263112T (pt) 2020-08-25
MX343130B (es) 2016-10-26
CY1123239T1 (el) 2021-10-29
HUE051484T2 (hu) 2021-03-01
IL197893A (en) 2015-06-30
IL238823A0 (en) 2015-06-30
US20170189421A1 (en) 2017-07-06
IL197893A0 (en) 2009-12-24
JP2014051530A (ja) 2014-03-20
ES2814343T3 (es) 2021-03-26
JP6175364B2 (ja) 2017-08-02
HUE036870T2 (hu) 2018-08-28

Similar Documents

Publication Publication Date Title
NO20091966L (no) Sammensetninger og fremgangsmater for a redusere proliferasjon av endometrie
MY161059A (en) Progesterone antagonists such as cdb-4214 in the treatment of embodimetriosis, uterine fibroids, dysmenorrhea, breast cancer etc
MY161549A (en) Progesterone antagonists such as cdb-4124 in the treatment of breast cancer
PH12018500045A1 (en) Compositions and methods for treating and diagnosing asthma
MX2009009581A (es) Indazoles usados para tratar trastornos mediados por el receptor de estrogenos beta.
IL258880A (en) Diarylhydantoin compounds
EA200900203A1 (ru) Избирательные модуляторы рецептора андрогенов, их аналоги, производные и применение
ATE494888T1 (de) Verwendung von gpr119-rezeptoragonisten zur vermehrung der knochenmasse und zur behandlung von osteoporose sowie kombinationstherapie dafür
MX2009006466A (es) Metodos de tratamiento de cancer con inhibidores del receptor del factor 1 de crecimiento similar a la insulina.
ATE514700T1 (de) Neues tetrazyklisches heteroatom mit als sexualsteroidhormon-rezeptormodulatoren geeigneten derivaten
NO20084007L (no) Spirokondenserte piperidiner som modulatorer av muskarinreseptorer
NO20062679L (no) Nye 17 β -hydroksysteroid-dehydrogenase-type 1-inhibitorer
BR112012012167A2 (pt) Metabólitos mamíferos de esteróides
SE0400346D0 (sv) Steroids for cancer treatment
TW200621244A (en) Modulators of muscarinic receptors
MXPA05008561A (es) Uso de esteroides para tratar personas que sufren de trastornos oculares.
CL2012002544A1 (es) Compuestos derivados de esteroides, inhibidores de la acción de la progesterona; composición farmacéutica; método para producir un efecto antiprogestacional; y método para tratar una afección dependiente de la progesterona tal como endometriosis y dolor asociado a esta, dismenorrea, fibromas uterinos y cáncer de ovario, entre otras.
TW200833710A (en) Treatment for spinal muscular atrophy
MX2020002684A (es) Composiciones topicas.
GB2459598A (en) Heterodimers and methods of using them
MX2007006382A (es) Moduladores de receptores muscarinicos.
UA98124C2 (ru) Применение антагониста прогестерона для лечения эндометриоза
UA96736C2 (ru) Ингибиторы pi3k для лечения эндометриоза
ATE445408T1 (de) Verwendung von prolactin in der prophylaktischen krebstherapie
ATE555793T1 (de) Verringerung der nebenwirkungen von aromatase- hemmern zur behandlung von brustkrebs

Legal Events

Date Code Title Description
CHAD Change of the owner's name or address (par. 44 patent law, par. patentforskriften)

Owner name: ALLERGAN PHARMACEUTICALS INTERNATIONAL LIMIT, IE

MM1K Lapsed by not paying the annual fees